Alpine Immune Sciences — Investor Presentation (August 2022)
39 slides from Alpine Immune Sciences's investor presentation, Aug 9, 2022
Slide 1: Leading the Next Evolution of Immunotherapies
Leading the Next Evolution of Immunotherapies August 2022 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not base
Slide 3: Leading the Next Evolution of Immunotherapies With a Highly Productive Directed Evolution Platform
Leading the Next Evolution of Immunotherapies With a Highly Productive Directed Evolution Platform Dual Costimulation (ICOS/CD28) Antagonist Systemic Lupus Erythematosus Phase 2 Partnered with Conditional CD28 Costimulator and Dual Checkpoint Inhibitor Advanced Malignancies Phase 1/1b Monotherapy Ex
Slide 4: ALPN-303 Dual B Cell Cytokine Antagonist
ALPN-303 Dual B Cell Cytokine Antagonist
Slide 5: ALPN-303: Engineered Inhibitor of BAFF (BLyS) and APRIL
ALPN-303: Engineered Inhibitor of BAFF (BLyS) and APRIL Clinically-Validated B cell Modulatory Pathways Immature B cell survival and maturation Plasma cell survival T-cell-independent antibody responses B cell regulation Class-switch recombination ALPN-303 APRIL Membrane BAFF Soluble BAFF TACI BCMA
Slide 6: ALPN-303: Potential Best-in-Class BAFF/APRIL Inhibitor
Responders (%) ALPN-303: Potential Best-in-Class BAFF/APRIL Inhibitor Optimized Design and Dual Inhibition Phase 2b (NCT02885610) Enhanced Dual Target Binding Best-In-Class Potential Variant TNF domain (vTD) Modest Efficacy in SLE SRI4 Response (%) Encouraging SLE Efficacy Belimumab (Benlysta®) Anti
Slide 7: ALPN-303 Has Significantly Enhanced Affinity for BAFF and APRIL as Compared to WT TACI-Fc
ALPN-303 has Significantly Enhanced Affinity for BAFF and APRIL as Compared to WT TACI-Fc BAFF ALPN-303 WT TACI-Fc CNBD, could not be determined ________________ *Telitacicept (Tai’ai®). APRIL BAFF APRIL ALPN-303 WT TACI-Fc* ALPN-303 WT TACI-Fc* KD (pM) 59.3 + 0.1 491 + 1 ~1.00 + 0.04 CNBD Telitacic
Slide 8: ALPN-303 Appears Superior to Existing BAFF/APRIL Inhibitors in vitro
ALPN-303 Appears Superior to Existing BAFF/APRIL Inhibitors in vitro BAFF Pathway APRIL Pathway BAFF+APRIL Pathway BION-1301: US Patent 10,377,830 B2 SEQ ID NO: 50 and SEQ ID NO: 52 * Generated at Alpine based on published sequences: ** Purchased clinical drug product: Belimumab (Benlysta®) Telitaci
Slide 9: ALPN-303: A More Potent B Cell Modulator in vivo
ALPN-303: A More Potent B Cell Modulator in vivo KLH Immunization Mouse Model Clearer Developmental B Cell Blockade Transitional-1 Transitional-2 Follicular Marginal Zone Germinal Center Plasma Cells ALPN-303 OD450 at 1:100,000 Fc Control Telitacicept Atacicept ALPN-303 Greater Reductions in IgG Ant
Slide 10: ALPN-303 Exhibits Encouraging Efficacy in Murine Connective Tissue Disease
ALPN-303 Exhibits Encouraging Efficacy in Murine Connective Tissue Disease Autoantibodies, as well as Renal Disease (Lupus) and Sialoadenitis (Sjögren’s-like) Fc Control ALPN-303 NZB/NZW F1 Histopathology Immune Deposits Proteinuria Anti-dsDNA Sialoadenitis Nephritis Renal Disease Fc control ALPN-30
Slide 11: ALPN-303 Exhibits Increased Exposure and Enhanced Ig Suppression in Non-human Primates
________________ Source: Atacicept PK data: Carbonatto et al. (2008) Toxicol Sci 105: 200–210 *Generated at Alpine based on the sequence included with the WHO INN submission, WHO Drug Information, Vol. 32, No. 4, 2018.; sequence subsequently confirmed by mass spectrometry analysis of telitacicept cl
Slide 12: RUBY-1: ALPN-303 Phase 1 in Adult Healthy Volunteers
RUBY-1: ALPN-303 Phase 1 in Adult Healthy Volunteers 8 mg IV 24 mg IV 240 mg IV 480 mg IV 960 mg IV IV SC 80 mg IV Safety: AE’s, immunogenicity, EKGs Pharmacokinetics Pharmacodynamics Serum immunoglobulins Circulating B cells and subsets 240 mg SC 480 mg SC 960 mg SC 80 mg SC ∆ after 1 dose: IgM, Ig
Slide 13: Single Dose ALPN-303 Preliminarily Reduces Serum Ig in Healthy Volunteers
Single Dose ALPN-303 Preliminarily Reduces Serum Ig in a Dose-Dependent Manner in Adult Healthy Volunteers baseline baseline baseline
Slide 14: ALPN-303 Early Development Plan
ALPN-303 Early Development Plan Enabling a Broad Lifecycle in Multiple Therapeutic Areas and Development Opportunities RUBY-2: Systemic Lupus Erythematosus Ph 2 RUBY-1: HV Ph 1 1 mo data RUBY-3: Renal Basket Ph 1b CMC: GMP1/2 2021 2022 2023 2024 2025 RUBY-4: Heme Basket Ph 1b RUBY-5: Derm Basket Ph
Slide 15: Davoceticept (ALPN-202) Oncology
Davoceticept (ALPN-202) Oncology: Conditional CD28 Costimulator and Dual Checkpoint Inhibitor
Slide 16: CD28 is Critical for T Cell Activity During Checkpoint Inhibition
CD28 is Critical for T Cell Activity During Checkpoint Inhibition 1 2 3 CD28 is a critical costimulatory receptor required for T cell activation. Its ligands are CD80 & CD86. Immune checkpoints like PD-1 and CTLA-4 inhibit T cells by interfering with CD28 signaling. Checkpoint inhibitors, e.g. anti-
Slide 17: Davoceticept Drives T-cell Activation Through Conditional CD28 Costimulation
T CELL PD-1 PD-L1 x CTLA-4 CD80/86 CD28 Davoceticept (ALPN-202) Drives T-cell Activation Through Conditional CD28 Costimulation and Dual Checkpoint Inhibition 1 2 3 …conditionally engages CD28 in the presence of PD-L1, subverting the latter into a CD28 costimulator …potentiates existing CD28 signali
Slide 18: First-In-Human Dose Escalation and Expansion Study of Davoceticept Monotherapy
A First-In-Human Dose Escalation and Expansion Study of Davoceticept (ALPN-202) Monotherapy in Advanced Malignancies 1 µg/kg 10 µg/kg 0.1 mg/kg 0.3 mg/kg 1 mg/kg 3 mg/kg MABEL-justified starting dose Single-subject cohorts IV Q1W regimen Advanced solid tumors, s/p checkpoints if appropriate Open-lab
Slide 19: Patient Baseline Characteristics
Patient Baseline Characteristics Characteristic Total (N=58) Age (yr, median, range) 60 (36-79) Female 25 (43%) Caucasian 46 (79%) Prior Lines of Therapy (median, range) Prior I/O Therapy / PD-(L)1 Inhibitor 4.0 (1-9) 24 (41%) / 17 (29%) Archival PD-L1 Expression CPS 0-10 / >10 34/51 (67%) / 17/51 (
Slide 20: Davoceticept Monotherapy Preliminary Safety
Davoceticept (ALPN-202) Monotherapy Preliminary Safety: Well-tolerated to 10mg/kg; Most Notable Events are irAEs Characteristic Subjects (N=58) Treatment-Related (TR) AE Gr 3+ 6 (10%) TR-Serious AE (SAE) / Gr 3+ 3 (5%) / 3 (5%) AE of Interest (AEI) Immune-related AE (irAE) / Gr 3+ Infusion-Related R
Slide 21: Immune-Related Adverse Events with Davoceticept
Immune-Related Adverse Events with Davoceticept Skin, Thyroid and GI Most Common, Especially at Mid-Range Doses irAEs, All Cohorts Subjects (N=58) Skin and Subcutaneous Tissue Rash Maculo-Papular Rash Macular Pruritus, Urticaria Night Sweats, Rash Papular, Rosacea 14 (24%) 7 (12%) 5 (9%) 2 (3%) each
Slide 22: Preliminary Antitumor Activity of Davoceticept Monotherapy
Preliminary Antitumor Activity of Davoceticept Monotherapy % ∆ From Baseline in SLD Best Response/Outcome Evaluable (N=48) Partial Response 2 (4%) Stable Disease 23 (48%) Progressive Disease 23 (48%) ∆ %SLD <0 11 (23%) On Treatment ≥ 6 mo 4 (8%) Data Extract: 13APR2022
Slide 23: Participant 20404: Papillary Renal Cell
Participant 20404: 68M Papillary Renal Cell Diagnosed 10/2020 Liebovich score 8, MSKCC poor risk Nephrectomy (pT3a N1) 11/2020 Metastatic disease 7/2021 PD-L1 CPS <1, TPS 0 Screening Cycle 6
Slide 24: NEON-1 Phase 1b Expansion Plans
NEON-1 Phase 1b Expansion Plans 2Q22 Melanoma Renal Cell % ∆ in SLD Dose (mg/kg) Dose Rationale: 1-3 mg/kg Indication Rationale: Melanoma, RCC, PD-L1+ Arm Cohorts Rationale Melanoma (Cutaneous) 1 & 3 mg/kg Q3W I/O-responsive; preliminary activity observed Amenable to on-study biopsy to confirm intra
Slide 25: Davoceticept Clinical Development Plan in Advanced Malignancies
Davoceticept (ALPN-202) Clinical Development Plan in Advanced Malignancies NEON-1 MONOTHERAPY Dose-dependent PK/PD; well tolerated to 10 mg/kg Manageable, anticipated immune-related toxicities to date Early evidence of clinical benefit in immune-resistant cancers Immuno-phenotyping consistent with a
Slide 26: Acazicolcept (ALPN-101) Autoimmune/Inflammatory Diseases
Acazicolcept (ALPN-101) Autoimmune/Inflammatory Diseases: Dual CD28/ICOS Antagonist
Slide 27: Acazicolcept Inhibits T Cell and T-Dependent B Cell Activation
Acazicolcept inhibits T cell and T-Dependent B cell activation Acazicolcept Acazicolcept ICOSL CD80/86 (B7) CD80/86 (B7) ICOSL ICOS CD28 CTLA4-lg* T-cell activation T cell T cell CD28 ICOS APC/B cell Available therapeutics block only the CD28 pathway Acazicolcept (ICOSL vlgD-Fc) blocks both CD28 and
Slide 28: Acazicolcept: A Uniquely Potent Immunomodulator of Diseased Cells
Acazicolcept (ALPN-101): A Uniquely Potent Immunomodulator of Diseased Cells % Inhibition >0 50 100
Slide 29: Acazicolcept Exhibits Dose-Dependent PK/PD and is Well-Tolerated in Humans
Acazicolcept (ALPN-101) Exhibits Dose-Dependent PK/PD and is Well-Tolerated in Humans Phase 1 Healthy Volunteer Single and Multiple Ascending Doses Dose-proportional PK/PD T1/2 ~4.3-8.6 days Bioavailability ~61% at 3 mg/kg Modest accumulation (≤1.66X) Well-Tolerated No cytokine storm or release, or
Slide 30: Synergy: Acazicolcept in Systemic Lupus Erythematosus Phase 2
Randomized, Double Blind, Placebo controlled, International N = 130 (65/arm) NCT04835441 Synergy: Acazicolcept in Systemic Lupus Erythematosus Phase 2 PHASE 2 Acazicolcept (ALPN-101) Placebo Week 1 Week 24 Primary Safety Secondary Efficacy (Disease Activity) Pharmacokinetics Immunogenicity (ADA) Pha
Slide 31: Alpine and AbbVie Strategic Partnership for Acazicolcept
Alpine and AbbVie Strategic Partnership for Acazicolcept $60M upfront payment and up to $805M for option exercise and success-based milestones Exclusive option and licensing agreement for development and commercialization of acazicolcept Validates Alpine’s Directed Evolution Platform Provides fundin
Slide 32: ALPN Directed Evolution Platform
ALPN Directed Evolution Platform
Slide 33: Turning a Diversity of Immune Proteins Into Novel Therapeutics
ALPN Directed Evolution Platform Turning a Diversity of Immune Proteins Into Novel Therapeutics Native Immune Domain Variant Domain Novel Therapeutic Candidate Directed Evolution ________________ Davoceticept (ALPN-202) (CD80 vIgD-Fc) Fc CD80 CD28 CTLA4 PD-L1 CD28 CTLA4 CD80 vlgD SELECT (SCREENING)
Slide 34: Corporate Update
Corporate Update
Slide 35: Alpine and Horizon Therapeutics Strategic Partnership
Alpine and Horizon Therapeutics Strategic Partnership $25M upfront payment and $15M equity investment with up to $1,524M in additional milestones Announced December 2021 Exclusive option and licensing agreement or the development and commercialization of up to four preclinical candidates Validates A
Slide 36: Strong Financial Position Following AbbVie and Horizon Partnerships
Strong Financial Position Following AbbVie and Horizon Partnerships and Recent Private Placements SUFFICIENT CASH RUNWAY TO FUND OPERATIONS INTO 2024 Received $105 million over ~first year of AbbVie Collaboration – Q321 Raised $91 million in private placement led by Frazier Life Sciences Public Fund
Slide 37: ALPN Pipeline & Anticipated Milestones
PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Partner PARTNERED PROGRAMS Acazicolcept (ALPN-101) Dual CD28/ICOS Antagonist Discovery Collaboration Immunology Next Generation TCR T-cell Therapies PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ANTICIPATED Milestones WHOLLY OWNED PROGRAMS IMMUNO-ONCOLOGY Da
Slide 38: Strong Leadership Team
Mitchell H. Gold, M.D. Peter Thompson, M.D. Min Cui, Ph.D. James N. Topper, M.D., Ph.D. Natasha Hernday Robert Conway Jörn Drappa, MD, PhD Chris Peetz Strong Leadership Team Deep Clinical, Regulatory, and Commercial Expertise LEADERSHIP TEAM Paul Rickey Chief Financial Officer Stanford Peng, M.D., P
Slide 39: Thank You
| 4 Aceineimmunesciences Thank You
Alpine Immune Sciences — Investor Presentation (August 2022) on 6ix